AI-based Clinical Trials Solution Providers Market Analysis

Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Neurological Disease)

The global AI-based clinical trials solution providers market is segmented and analyzed for demand and supply by application into oncology, cardiovascular diseases, metabolic diseases, neurological diseases, and others. Out of these, the oncology segment is anticipated to garner the largest market share over the forecast period. Owing to the increasing prevalence of cancer worldwide and the increasing number of drug trials. In 2019, oncology accounted for the most popular therapy area for non-industry-sponsored clinical trials, estimated for 26% of all clinical trials. In the recent times, there has been rise in drug based clinical trials in oncological research, this in turn have raised the demand for AI-based equipment in the clinical research. Moreover, growing number of market players opting for oncology-based simulated instruments for clinical preliminaries is driving the growth of this segment.

Clinical Trial Phase (Phase-I, Phase-II, Phase-III)

The global AI-based clinical trials solution providers market is segmented and analyzed for demand and supply by clinical trial phase into Phase-I, Phase II, and Phase III. The Phase II segment is expected to account for the fastest market share in the forecast period. Phase II held a market share of 46.1% in 2022, owing to the prevalence of a large number of clinical trials in this segment. The factor driving the growth of this segment is the growing incorporation of AI tools for immediate results from the desired outcome of drug trials and also the collection of data at the same time. Additionally, Phase I segment is anticipated to show the fastest growth rate of 24.2% in the forecast period. As phase I is advantageous for patient retention, better trial design and patient recruitment, the ai-based solution is expected to grow in the forecast period.

Our in-depth analysis of the global market includes the following segments:

By Application	Oncology Cardiovascular Diseases Metabolic Diseases Neurological Disease Others
By Clinical Trial Phase	Phase-I Phase-II Phase-III
By End User	Pharmaceutical Companies Academic Researcher Others

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of AI-based clinical trials solution providers is evaluated at USD 1.73 billion.

The AI-based clinical trials solution providers market size was over USD 1.47 billion in 2024 and is expected to exceed USD 19.22 billion by the end of 2037, witnessing over 21.6% CAGR during the forecast period i.e., between 2025-2037. The market expansion is attributed to the increasing adoption of AI-based platforms to enhance the accuracy and productivity of clinical trials at different stages.

North America industry is predicted to have the highest growth through 2037, owing to increasing penetration of AI-based tools and increasing government initiatives for adoption in different medical projects in the region.

The major players in the market include Unlearn.AI, Inc., Saama Technologies, LLC., Antidote Technologies, Inc., Biosymetrics, Pharmaceutical Pipeline Enhancement Strategies, LLC, Deep 6 AI Inc., Innoplexus AG, Mendel.ai, Intelligencia, Median Technologies.

AI-based Clinical Trials Solution Providers Market Analysis